Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-LiTE: Liraglutide and Exercise for Weight Loss Maintenance
NCT04122716Phase 4Unknown
- Start
- Sep 2016
- Primary completion
- Nov 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, triple-blind trial of liraglutide in obesity (4 arms). Primary endpoint: Change in body weight at 52 weeks. Status: unknown.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04122716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04122716.